Zai Lab Reports Improved Overall Survival in Phase 3 Trial of Tivdak in Cervical Cancer Patients

MT Newswires Live01-15

Zai Lab (ZLAB) said Wednesday that data from the China subpopulation of a global phase 3 trial showed an improved overall survival after treatment with Tivdak in patients with recurrent or metastatic cervical cancer compared with chemotherapy.

The company said the China results were consistent with those seen in the global population as the drug candidate showed a 45% decrease in the risk of death compared with chemotherapy.

Main secondary endpoints of progression-free survival and objective response rate also "favored treatment with Tivdak compared to chemotherapy," Zai Lab said.

The company said it plans to file a new drug application with China's National Medical Products Administration in Q1.

ZLAB shares were up 2.8% in early trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2503965642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503965642","market":"us","top_or_hot":-1,"title":"Zai Lab Reports Improved Overall Survival in Phase 3 Trial of Tivdak in Cervical Cancer Patients","media":"MT Newswires Live","content":"<html><body><p> Zai Lab (ZLAB) said Wednesday that data from the China subpopulation of a global phase 3 trial showed an improved overall survival after treatment with Tivdak in patients with recurrent or metastatic cervical cancer compared with chemotherapy.</p><p>The company said the China results were consistent with those seen in the global population as the drug candidate showed a 45% decrease in the risk of death compared with chemotherapy.</p><p>Main secondary endpoints of progression-free survival and objective response rate also \"favored treatment with Tivdak compared to chemotherapy,\" Zai Lab said.</p><p>The company said it plans to file a new drug application with China's National Medical Products Administration in Q1.</p><p>ZLAB shares were up 2.8% in early trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Reports Improved Overall Survival in Phase 3 Trial of Tivdak in Cervical Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Reports Improved Overall Survival in Phase 3 Trial of Tivdak in Cervical Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-15 22:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zai Lab (ZLAB) said Wednesday that data from the China subpopulation of a global phase 3 trial showed an improved overall survival after treatment with Tivdak in patients with recurrent or metastatic ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZLAB","symbol_name":"再鼎医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503965642","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503965642","pubTimestamp":1736951508,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zai Lab  said Wednesday that data from the China subpopulation of a global phase 3 trial showed an improved overall survival after treatment with Tivdak in patients with recurrent or metastatic cervical cancer compared with chemotherapy.The company said the China results were consistent with those seen in the global population as the drug candidate showed a 45% decrease in the risk of death compared with chemotherapy.Main secondary endpoints of progression-free survival and objective response rate also \"favored treatment with Tivdak compared to chemotherapy,\" Zai Lab said.The company said it plans to file a new drug application with China's National Medical Products Administration in Q1.ZLAB shares were up 2.8% in early trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZLAB":"再鼎医药","BK4531":"中概回港概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4526":"热门中概股","BK4548":"巴美列捷福持仓"},"translate_title":"再鼎医药报告Tivdak在宫颈癌患者中的3期试验中提高了总生存期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZLAB":0.9},"content_text":"Zai Lab (ZLAB) said Wednesday that data from the China subpopulation of a global phase 3 trial showed an improved overall survival after treatment with Tivdak in patients with recurrent or metastatic cervical cancer compared with chemotherapy.The company said the China results were consistent with those seen in the global population as the drug candidate showed a 45% decrease in the risk of death compared with chemotherapy.Main secondary endpoints of progression-free survival and objective response rate also \"favored treatment with Tivdak compared to chemotherapy,\" Zai Lab said.The company said it plans to file a new drug application with China's National Medical Products Administration in Q1.ZLAB shares were up 2.8% in early trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503965642"}